![](\"http:\/\/www.erzurumflas.com\/wp-content\/uploads\/2015\/11\/kanser-tedavilerinde-yeni-ilaclar-umut-veriyor_042386b.jpg\")
Onkolojik tedavilerin \u00e7ok h\u0131zl\u0131 de\u011fi\u015fti\u011fini ve hedefli tedavilerin ard\u0131ndan immuno-onkoloji, ba\u011f\u0131\u015f\u0131kl\u0131k sistemini g\u00fc\u00e7lendiren ila\u00e7larla tedaviye ge\u00e7ildi\u011fini anlatan Prof. Dr. G\u00f6khan Demir, yeni ila\u00e7lar\u0131n umut verdi\u011fini s\u00f6yledi.<\/p>\n
4. Akdeniz Multidisipliner Onkoloji Forumu Kongresi (4th Congress of the Mediterranean Multidisiplinary Oncology Forum-MMOF) \u2019nde \u0130mmuno-onkoloji ila\u00e7lar\u0131n\u0131n \u00f6nemine ve tedaviye olan etkisine dikkat \u00e7ekildi.<\/p>\n
T\u00fcrk T\u0131bbi Onkoloji Derne\u011fi ve Akdeniz Multidisipliner Onkoloji Forumu Ba\u015fkan\u0131 Prof. Dr. G\u00f6khan Demir, immuno-onkoloji ila\u00e7lar\u0131 i\u00e7in Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131\u2019na ba\u015fvuruldu\u011funu s\u00f6yleyerek, bu ila\u00e7lar i\u00e7in insani kullan\u0131m programlar\u0131 a\u00e7\u0131ld\u0131\u011f\u0131n\u0131 belirtti. \u015eu anda bir\u00e7ok klinik ara\u015ft\u0131rman\u0131n oldu\u011funa dikkat \u00e7eken Demir, b\u00f6brek kanserleriyle ilgili bu ila\u00e7lar\u0131n onaylanarak, T\u00fcrkiye\u2019de yeni bir klinik \u00e7al\u0131\u015fma alan\u0131 a\u00e7\u0131ld\u0131\u011f\u0131n\u0131, b\u00f6brekte ve melanomda insani kullan\u0131m program\u0131n\u0131n a\u00e7\u0131k oldu\u011funu s\u00f6yledi.<\/p>\n
KANSERDE CO\u011eRAF\u0130 FARKLILIKLAR \u00d6NEM TA\u015eIYOR<\/p>\n
MMOF\u2019un yakla\u015f\u0131k 800 \u00fcyesi olan bir onkoloji birli\u011fi oldu\u011funu s\u00f6yleyen Demir, \u201cKlinik onkolojinin \u00e7ok \u00f6nemli bir yan\u0131 da co\u011frafi farkl\u0131l\u0131klar g\u00f6stermesidir. Baz\u0131 kanser t\u00fcrleri, baz\u0131 co\u011frafyalarda daha s\u0131k kar\u015f\u0131m\u0131za \u00e7\u0131k\u0131yor. Akdeniz \u00fclkelerinde \u00f6zellikle akci\u011fer, mide, karaci\u011fer ve mesene kanserleri bat\u0131 toplumlar\u0131na oranla daha s\u0131k g\u00f6r\u00fcl\u00fcyor. Kongremizde bu b\u00f6lgesel farkl\u0131l\u0131k g\u00f6steren kanser t\u00fcrlerini, masaya yat\u0131r\u0131yoruz\u201d ifadelerini kulland\u0131.<\/p>\n
Global onkolojiden b\u00f6lgesel onkolojiye ge\u00e7i\u015f ya\u015fand\u0131\u011f\u0131n\u0131 dile getiren Demir, “Mide kanseri b\u00fct\u00fcn d\u00fcnyada g\u00f6r\u00fcl\u00fcyor ama bizim co\u011frafyam\u0131zda g\u00f6r\u00fclen t\u00fcm\u00f6rler bat\u0131 co\u011frafyas\u0131ndan farkl\u0131. Bat\u0131 co\u011frafyas\u0131nda \u00f6nemsenmeyen, art\u0131k \u00fczerlerinde \u00e7ok fazla \u00e7al\u0131\u015fma, ara\u015ft\u0131rma yap\u0131lmayan t\u00fcm\u00f6rler bizim co\u011frafyam\u0131zda hala \u00e7ok etkili. \u00d6rne\u011fin mide kanseriyle, karaci\u011fer kanseriyle ilgili ABD\u2019de art\u0131k \u00e7ok az ara\u015ft\u0131rma yap\u0131l\u0131yor ama bu kanserler bizim bulundu\u011fumuz co\u011frafyada yani M\u0131s\u0131r\u2019da, T\u00fcrkiye\u2019de, Yunanistan\u2019da, Balkanlar\u2019da hala \u00f6nemli kanserler” diye konu\u015ftu.<\/p>\n
\u00d6NEM\u0130N\u0130 KORUYAN HASTALIKLAR MASAYA YATIRILDI<\/p>\n
Demir, toplant\u0131lar\u0131n birinci amac\u0131n\u0131n, d\u00fcnya genelinde \u00f6nemini zamanla yitirmi\u015f olsa da b\u00f6lge i\u00e7in hala \u00f6nemini koruyan hastal\u0131klar\u0131n tart\u0131\u015f\u0131lmas\u0131 oldu\u011funu belirtti.<\/p>\n
Onkolojik tedavilerin \u00e7ok h\u0131zl\u0131 de\u011fi\u015fti\u011fini ve hedefli tedavilerin ard\u0131ndan immuno-onkoloji, ba\u011f\u0131\u015f\u0131kl\u0131k sistemini g\u00fc\u00e7lendiren ila\u00e7larla tedaviye ge\u00e7ildi\u011fini anlatan Demir, onkolojide de\u011fi\u015fimin mali k\u00fclfet getirdi\u011fini, ila\u00e7lar\u0131n fiyatlar\u0131n\u0131n kemoterapi ila\u00e7lar\u0131na oranla 100 kat art\u0131\u011f\u0131n\u0131, toplant\u0131da ila\u00e7lar\u0131n artan maliyetinin nas\u0131l kar\u015f\u0131lanabilece\u011fi konusunun da ele al\u0131naca\u011f\u0131n\u0131 dile getirdi.<\/p>\n
Demir, immuno-onkoloji ila\u00e7lar\u0131 i\u00e7in Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131\u2019na ba\u015fvuruldu\u011funu belirterek, “Bu ila\u00e7lar i\u00e7in insani kullan\u0131m programlar\u0131 a\u00e7\u0131ld\u0131. Yani bug\u00fcn geri \u00f6deme program\u0131nda olmasa bile ba\u015fvurulabiliyor. \u015eu anda bir\u00e7ok da klinik ara\u015ft\u0131rma var. \u00d6rne\u011fin b\u00f6brek kanserleriyle ilgili bu ila\u00e7lar onayland\u0131 ve T\u00fcrkiye\u2019de yeni bir klinik \u00e7al\u0131\u015fma a\u00e7\u0131ld\u0131. B\u00f6brekte ve melanomda insani kullan\u0131m program\u0131 a\u00e7\u0131k” dedi.<\/p>\n
\u00c7ALI\u015eMALAR HASTALARA UMUT VERMEYE DEVAM ED\u0130YOR<\/p>\n
Prof. Dr. Paris Kosmidis ise onkolojinin yeni alan\u0131 olan immuno-onkolojiye de\u011finerek, akci\u011fer gibi belli t\u00fcm\u00f6r gruplar\u0131nda bu tedavi uyguland\u0131\u011f\u0131 zaman, eskiden hastal\u0131k ileri evrede dahi olsa hasta 1 y\u0131l ya\u015fat\u0131labilirken, bug\u00fcn \u00e7ok daha uzun y\u0131llar ya\u015fat\u0131labildi\u011fini ve \u00e7ok az yan etkinin ortaya \u00e7\u0131kt\u0131\u011f\u0131n\u0131 s\u00f6yledi. Kemoterapiye oranla s\u00f6z konusu ila\u00e7lar\u0131n ya\u015fam s\u00fcresini art\u0131rd\u0131\u011f\u0131n\u0131 belirten Kosmidis, \u00e7al\u0131\u015fmalar\u0131n umut verici \u015fekilde devam etti\u011fini, hastaya do\u011fru ila\u00e7 vererek, maliyetlerin d\u00fc\u015f\u00fcr\u00fclebilece\u011fini ifade etti.<\/p>\n
Prof. Dr. Dimitris Bafaloukos de, artan ya\u015fam s\u00fcrelerine dikkat \u00e7ekerek, \u201c2010 y\u0131l\u0131ndan \u00f6nce melanoma hastalar\u0131nda sa\u011f kal\u0131m oran\u0131 3- 6 ay aras\u0131ndayd\u0131, bu yeni ku\u015fak ila\u00e7larla 3-6 y\u0131l ya\u015fatabildi\u011fimiz hastalar oldu. Hatta bir grup hastay\u0131 10 y\u0131ldan daha uzun ya\u015fatabiliyoruz. Yo\u011fun \u00e7al\u0131\u015fmalar s\u00fcr\u00fcyor ve iyi geli\u015fmeler bekleniyor\u201d diye konu\u015ftu.<\/p>\n
AKC\u0130\u011eER KANSER\u0130NDE UMUT \u0130MM\u00dcNOTERAP\u0130\u2019DE<\/p>\n
\u0130mm\u00fcnoterapi alan\u0131nda \u00e7ok h\u0131zl\u0131 ve etkili geli\u015fmeler ya\u015fand\u0131\u011f\u0131n\u0131n alt\u0131n\u0131 \u00e7izen Prof. Dr. Ba\u015fak Oyan Ulu\u00e7, kanser imm\u00fcnoterapisindeki son geli\u015fmeler hakk\u0131nda \u015funlar\u0131 s\u00f6yledi:<\/p>\n
\u201cBir ki\u015fiye kanser tan\u0131s\u0131 konulmu\u015fsa, bu ba\u011f\u0131\u015f\u0131kl\u0131k sistemi h\u00fccrelerinin kanserle\u015fmi\u015f h\u00fccreleri tan\u0131ma veya yok etmede bir eksikli\u011fi oldu\u011fu anlam\u0131na gelir. Son y\u0131llarda ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin kanseri yok etmesini engelleyen tolerans mekanizmalar\u0131n\u0131n ke\u015ffedilmesinden sonra, bu mekanizmalar\u0131 geriye d\u00f6nd\u00fcrmeye y\u00f6nelik ila\u00e7lar da geli\u015ftirildi. Art\u0131k imm\u00fcnoterapiyle insan v\u00fccudunun yeniden t\u00fcm\u00f6re sald\u0131rmas\u0131 sa\u011flanabiliyor. Bu sene ABD\u2019de iki imm\u00fcnoterapi ilac\u0131, metastatik k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanserinde sa\u011flad\u0131\u011f\u0131 yarar sebebiyle ruhsat ald\u0131. Bu ila\u00e7lar\u0131n toksik etkileri olduk\u00e7a d\u00fc\u015f\u00fck ve etkileri \u00e7ok daha uzun s\u00fcreli. Yani ikinci umut verici tedavi imm\u00fcnoterapi olacak\u201d.